Key facts
- Hilltop Bio’s last known valuation is $22.0M (Mar 2025).
- It has raised $8.1M; the latest was Later Stage VC ($5.3M) in Mar 2025.
- Notable investors include Band of Angels, Launchpad Venture Group, SideCar Angels, Moodoos Investments, Ag Startup Engine — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Hilltop Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Hilltop Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hilltop Bio
Operator of a veterinary biotechnology company intended to develop innovative cell signaling therapies to help reduce animal inflammation. The company identifies key inflammatory diseases in companion and performance animals and works to provide targeted treatments to help reduce inflammation and normalize damaged tissue function, enabling animal owners to get fast and efficient healing for horses and dogs suffering from several conditions.
- Sector
- Business Products and Services (B2B)
- HQ
- Norwood, MA, United States
- Founded
- 2018
- Employees
- 10
- Website
- hilltopbio.com/
- Ownership
- Privately Held (backing)
Hilltop Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hilltop Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hilltop Bio in its N-PORT filings yet. We sweep new filings monthly.